Screener
Enliven Therapeutics ELVN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's EPS (diluted)?
- Enliven Therapeutics (ELVN) reported EPS (diluted) of -$0.38 in Q1 2026.
- How has Enliven Therapeutics's EPS (diluted) changed year-over-year?
- Enliven Therapeutics's EPS (diluted) increased by 33.3% year-over-year, from -$0.57 to -$0.38.
- What is the long-term trend for Enliven Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EPS (diluted) has grown at a -12.0% compound annual growth rate (CAGR), from -$3.10 to -$1.86.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Enliven Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude